Inositol
Carbocyclic SugarAlso known as: Myo-inositol · D-chiro-inositol · Vitamin B8
A carbocyclic sugar with roles in cell signaling and insulin sensitivity. Studied for OCD, panic disorder, depression, and PCOS. Psychiatric doses (12–18g/day) are much higher than metabolic doses (2–4g).
How expert claims hold up
96 of 96 claims assessed22 of 96 assessed claims supported or partially supported by published research
Expert Consensus
Evidence Summary
Inositol, particularly myo-inositol (MI) and D-chiro-inositol (DCI), has accumulated a meaningful body of human research across several health areas, with the strongest evidence concentrated in polycystic ovary syndrome (PCOS), gestational diabetes prevention, thyroid health, and fertility. Multiple meta-analyses and systematic reviews are available, lending more credibility to findings in these areas than is typical for dietary supplements. Overall, the evidence suggests genuine biological activity — particularly around insulin signaling and hormonal regulation — though important questions about optimal dosing, long-term outcomes, and specific populations remain open. The most consistently supported application is PCOS management, where multiple meta-analyses and systematic reviews point to benefits in metabolic and hormonal markers. Myo-inositol at doses of approximately 2–4 grams per day, sometimes combined with D-chiro-inositol in a 40:1 ratio, appears to improve insulin sensitivity and menstrual regularity in affected women. Two meta-analyses also support the use of inositol supplementation during pregnancy to reduce the risk of gestational diabetes mellitus, a clinically meaningful outcome. For thyroid health, particularly subclinical hypothyroidism and Hashimoto's thyroiditis, systematic reviews and network meta-analyses suggest inositol may offer modest benefit, though findings are less definitive. Evidence for fertility support (including IVF outcomes and age-related ovarian decline) is supported by meta-analyses but remains preliminary. In psychiatric conditions such as bipolar disorder, the evidence base is weak and no large well-powered RCTs exist to draw firm conclusions. Several important caveats apply across this body of evidence. Many studies suffer from small sample sizes, short durations, and heterogeneous populations, limiting generalizability. The expert consensus classification rated 74 out of 96 specific claims as having insufficient evidence, with only one claim fully supported and 21 partially supported — underscoring that much of what is commonly said about inositol outpaces the science. The 40:1 MI:DCI dosing ratio for PCOS, while widely cited, is based on physiological rationale and early data rather than definitive dose-comparison trials. For psychiatric and fertility applications especially, the evidence is too preliminary to support strong clinical recommendations.
Read full evidence summary →Top studies
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
Antioxidants and Fertility in Women with Ovarian Aging: A Systematic Review and Meta-Analysis.
Antioxidants and Fertility in Women with Ovarian Aging: A Systematic Review and Meta-Analysis.
Expert Mentions
All 96 mentions
“We don't have large, well-powered RCTs.”
There are no large, well-powered RCTs for inositol in psychiatric conditions.
The expert's claim that there are no large, well-powered RCTs for inositol in psychiatric conditions receives partial support from the available evidence. The WFSBP/CANMAT guidelines meta-analysis (PM…
“I'm careful not to position it as a replacement for established treatments, particularly for conditions like OCD where the evidence for CBT and SSRIs is very strong.”
Inositol should not be positioned as a replacement for established treatments, particularly for OCD where evidence for CBT and SSRIs is very strong.
None of the 10 provided studies directly address inositol's efficacy for OCD or compare it against CBT and SSRIs for psychiatric indications. The most relevant study (PMID 35311615, WFSBP/CANMAT nutra…
Safety, interactions & who should avoid Inositol
generally_recognized_safe
Inositol is generally considered well-tolerated at commonly studied doses, with gastrointestinal symptoms (nausea, bloating) being the most frequently reported side effects. Formal safety data from long-term or high-dose studies are limited, so caution is warranted outside well-studied populations such as women with PCOS or at risk for gestational diabetes.
Inositol is generally well-tolerated; the most common adverse effects are gastrointestinal (nausea, flatulence, diarrhea) and tend to occur at higher doses (≥12–18 g/day). It appears safe in pregnancy at doses studied for gestational diabetes prevention, but use during pregnancy should only occur under medical supervision.
Who should avoid it
Individuals with bipolar disorder should use caution at high doses without psychiatric supervision, as evidence is mixed and interaction with mood-stabilizing medications is possible. Pregnant individuals should consult a healthcare provider before use despite generally favorable safety data. Those with known hypersensitivity to inositol should avoid it.
Known interactions
- ·May have additive effects with insulin or oral hypoglycemic agents due to insulin-sensitizing properties — blood glucose monitoring is advisable
- ·Possible interaction with lithium in bipolar disorder contexts, as inositol depletion is part of lithium's proposed mechanism — combined use should be medically supervised
- ·May theoretically interact with SSRIs or other serotonergic agents when used at high psychiatric doses, though direct interaction data are limited
Pregnancy & breastfeeding
Our sources specifically flag pregnancy or breastfeeding considerations for Inositol — see the cautions above.
We don’t assign pregnancy-safety ratings. Many supplements lack adequate safety data in pregnancy and breastfeeding, and the absence of a warning here does not mean a supplement is safe to take. Don’t start, stop, or continue any supplement while pregnant or nursing without your OB-GYN or midwife.
Read: Supplements during pregnancy & breastfeeding →This is educational information only. Consult a healthcare provider before starting any supplement.
Stay on top of Inositol research
One email a month when new research on Inositol is published.
Double opt-in · unsubscribe anytime · not medical advice.
No buy link — yet
We only link products that meet our sourcing standards. We haven’t linked one for Inositol yet. Our standards →
Key findings
- ·Multiple meta-analyses support myo-inositol (typically 2–4 g/day) for improving metabolic and hormonal parameters in women with PCOS, representing the strongest evidence base for this supplement.
- ·Two meta-analyses of randomized controlled trials indicate that myo-inositol supplementation during pregnancy may reduce the incidence of gestational diabetes mellitus.
- ·Systematic reviews and network meta-analyses suggest inositol may provide modest benefit in Hashimoto's thyroiditis and subclinical hypothyroidism, though evidence is less definitive.
Evidence gaps
- ·Long-term safety and efficacy data are lacking across most indications — most trials are short-duration and do not establish whether benefits persist or whether adverse effects emerge with extended use.
- ·The optimal dose, form (myo-inositol vs. D-chiro-inositol vs. combined), and ratio for specific conditions have not been established through rigorous head-to-head dose-comparison trials.
- ·Evidence in psychiatric populations is particularly underdeveloped, with no large randomized controlled trials available to confirm or refute signals from smaller studies.